Investigation and management of biochemical recurrence in prostate cancer by using prostate-specific membrane antigen (PSMA) PET-CT imaging (68Ga-PSMA-PET): A retrospective study

Trial Profile

Investigation and management of biochemical recurrence in prostate cancer by using prostate-specific membrane antigen (PSMA) PET-CT imaging (68Ga-PSMA-PET): A retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 15 Mar 2018 New trial record
    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top